Context Therapeutics (NASDAQ:CNTX) Releases Earnings Results, Beats Expectations By $0.01 EPS

Posted by Tyrone Williams on Mar 22nd, 2025

Context Therapeutics (NASDAQ:CNTX – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01, reports.

Context Therapeutics Stock Performance

Shares of Context Therapeutics stock opened at $0.77 on Friday. Context Therapeutics has a 1 year low of $0.64 and a 1 year high of $2.75. The firm’s 50-day simple moving average is $0.85 and its 200-day simple moving average is $1.44. The firm has a market cap of $57.88 million, a PE ratio of -0.85 and a beta of 2.06.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. D. Boral Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research report on Friday. Finally, JMP Securities assumed coverage on Context Therapeutics in a report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $6.17.

View Our Latest Research Report on CNTX

About Context Therapeutics

(Get Free Report)

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.